GoAI
Get started
ProMIS Neurosciences, Inc. logo

ProMIS Neurosciences, Inc.

PMN

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$14.51

−$0.40 · -2.68%

Aug 21, 4:00 PM ET

PMN company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

25

Expensive

Momentum

78

Gaining

Sentiment

66

Bullish

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.

Industry
Biotechnology
Sector
Healthcare
Headquarters
CA
CEO
Neil K. Warma
Listed since
Jan 10, 2007
Employees
11

Market position

Day range

Current $14.51

52-week range

Current $14.51

Open
$14.84
Previous close
$14.91
Volume
5.54K
0.08× average
Average volume
68.32K
Average daily volume
Market cap
18.97M USD
Beta
-0.22
Market reference 1
50-day average
$13.158
+10.28% above average
200-day average
$12.2391
+18.55% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-0.82×
P/B (TTM)
2.69×
P/S (TTM)
0×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%

Financial health

Debt / equity
0×

Financial statements

Income trends

Operating income

−40.17M USD-138.70%

Net income

−39.72M USD−42.5M USD
Income trends across reported periods2.34B USD−7.01B USD−16.37B USD−25.72B USDOperating income, FY2021: −10.57M USDOperating income, FY2022: −23.38B USDOperating income, FY2023: −18.9M USDOperating income, FY2024: −16.83M USDOperating income, FY2025: −40.17M USDNet income, FY2021: −11.98M USDNet income, FY2022: −18.06B USDNet income, FY2023: −17.51M USDNet income, FY2024: 2.78M USDNet income, FY2025: −39.72M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −10.57M USD. Operating income FY2022 −23.38B USD. Operating income FY2023 −18.9M USD. Operating income FY2024 −16.83M USD. Operating income FY2025 −40.17M USD. Net income FY2021 −11.98M USD. Net income FY2022 −18.06B USD. Net income FY2023 −17.51M USD. Net income FY2024 2.78M USD. Net income FY2025 −39.72M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue————16.68K USD
Cost of goods sold33.36M USD—10.44M USD—5.85M USD
Gross profit−33.36M USD—−10.44M USD—−5.84M USD
Research and development33.38M USD10.64M USD7.88M USD16.09B USD4.95M USD
Selling, general, and administrative6.79M USD6.19M USD6.38M USD7.29B USD3.31M USD
Operating expenses40.17M USD16.83M USD8.45M USD23.38B USD4.63M USD
Interest income————4.73K USD
Interest expense—76.78K USD201.39K USD282.06M USD416.29K USD
Depreciation and amortization−724.69K USD—28.04K USD—45.83K USD
Operating income−40.17M USD−16.83M USD−18.9M USD−23.38B USD−10.57M USD
Net income−39.72M USD2.78M USD−17.51M USD−18.06B USD−11.98M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 5 misses, 0 met estimates
Average EPS surprise
+50.13%
11 comparable reports
Latest EPS result
-1.28
Estimate -1.38 · Beat by 7.25%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.43-2.88-5.34-7.79Q1 '25BeatQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 31, 2025: actual -0.5, estimate -3.5, surprise +85.71%, Beat. Q2 2025, reported May 12, 2025: actual -5.25, estimate -3, surprise -75.00%, Miss. Q3 2025, reported Aug 13, 2025: actual -7.25, estimate -5.5, surprise -31.82%, Miss. Q4 2025, reported Nov 12, 2025: actual -6, estimate -3.75, surprise -60.00%, Miss. Q1 2026, reported Mar 30, 2026: actual -4.11, estimate -4.22, surprise +2.61%, Beat. Q2 2026, reported May 11, 2026: actual -1.26, estimate -1.06, surprise -18.87%, Miss. Q3 2026, reported Aug 13, 2026: actual -1.28, estimate -1.38, surprise +7.25%, Beat. Q4 2026, reported Nov 11, 2026: actual —, estimate -1.27, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

3 ratings

Limited analyst sample: 3 ratings. Interpret the distribution with caution.

Strong buy00%
Buy3100%
Hold00%
Sell00%
Strong sell00%

Corporate actions

Corporate action history

Stock split

Effective Nov 28, 2025

1:25

Stock split

Effective Jun 28, 2022

1:60

PMN peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research PMN

research.disclaimer